Dutch doctors resist pharma firm’s 500-fold price hike
pharmafile | September 3, 2018 | News story | Sales and Marketing | Netherlands, leadiant, pharma, pricing
A group of Dutch doctors and health advocates are taking action against the Italian pharmaceutical firm Leadiant Biosciences who have increased the price of a lifesaving drug by 500 times its original price.
The Dutch Pharmaceutical Accountability Foundation, a non-profit organisation set up to tackle high drug prices in the Netherlands is set to file a claim against the price hiking firm with The Netherlands’ Authority for Consumers and Markets.
Lediant are accused of having abused their market power after they increased the price of their drug chenodeoxycholic acid (CDCA) from €300 a year to €150,000 each year after they gained full control of supplies and approval for the treatment of the rare disease cerebrotendinous xanthomatosis (CTX) from EU regulators in 2017.
Separately, doctors treating CTX at the Amsterdam Medical Center are seeking to develop a low cost version of the drug in an effort to undercut the Italian company. The case is anticipated to spark fresh debate around orphan drug legislation which allows manufacturers to win exclusivity on drugs that have been approved for the treatment of rare diseases, even after patents have expired.
Although CDCA is a relatively simple chemical compound, Leadiant Biosciences acquired rival suppliers and withdrew the drug from the market. While CDCA had been prescribed by Dutch doctors off label for the treatment of CDCA, Leadiant relaunched the drug after gaining approval for the treatment of CTX. This effectively gave them a monopoly which allowed them to raise prices to astronomical levels.
Carla Hollak from the Amsterdam Medical Centre commented: “This is essential medication. I’m fully against these kind of actions by the pharmaceutical industry to gain a monopoly and sell a drug for a price that suggests it has cost an enormous amount.”
Louis Goss
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …
